TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 7522415
Drug: Neoadjuvant total
Normalized name: Colgate Total Mouthwash
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant total androgen ablation therapy (3 months of goserelin acetate and flutamide)
Study: 3381269
Drug: Conventional therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional therapy (corticosteroids/Leukeran)
Study: 28684357
Drug: A‐Helping‐Hand (AHH)
Approvals — FDA: no, EMA: no, PMDA: no
Description: A‐Helping‐Hand (AHH) intervention with 6 weekly psychoeducational sessions and boosters
Study: 22551128
Drug: Low-dose radioiodine
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose radioiodine
Study: 22551128
Drug: High-dose radioiodine
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose radioiodine
Study: 24997645
Drug: Low-dose radioiodine
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose radioiodine (pT2-4 cancer)
Study: 24997645
Drug: High-dose radioiodine
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose radioiodine (pT2-4 cancer)
Study: 24997645
Drug: Low-dose radioiodine
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose radioiodine (total thyroidectomy)
Study: 24997645
Drug: High-dose radioiodine
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose radioiodine (total thyroidectomy)
Study: 24997645
Drug: Low-dose radioiodine
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose radioiodine (thyrotropin α stimulation)
Study: 24997645
Drug: High-dose radioiodine
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose radioiodine (thyrotropin α stimulation)
Study: 24997645
Drug: Moderate-dose radioiodine
Normalized name: Radioiodine
DrugBank: Iodide I-131 (DB09293)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moderate-dose radioiodine
Study: 19366274
Drug: Frovatriptan once
Approvals — FDA: no, EMA: no, PMDA: no
Description: Frovatriptan once daily (day 1: 5 mg; days 2-6: 2.5 mg)
Study: 19366274
Drug: Frovatriptan twice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Frovatriptan twice daily (day 1: 5 mg [10 mg total]; days 2-6: 2.5 mg [5 mg total])
Study: 15290418
Drug: Intrathecal morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intrathecal morphine (0.5 mg) + noradrenaline (5 micro g)
Study: 31884409
Drug: Nasal mask
Normalized name: sulfur
DrugBank: Octasulfur (DB09353)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nasal mask combined with oral shield device (NMS)
Study: 17616259
Drug: THEME (Update
Approvals — FDA: no, EMA: no, PMDA: no
Description: THEME (Update day plus 12 weekly worksheets, feedback to audiotaped sessions, and three 30 minute sessions of telephone coaching)
Study: 12377405
Drug: Nicotine 21
Normalized name: NICOTINE 21MG/24HR PATCH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicotine 21 mg transdermal patch
Study: 10203379
Drug: Interleukin (IL)‐2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interleukin (IL)‐2 therapy
Study: 8880837
Drug: Inflammatory mediators
Normalized name: Arthriten Inflammatory Pain
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inflammatory mediators (IM) injected in acidic solution (BK, 5-HT, HIS, PGE2) at concentrations of 10(-7) M, 10(-6) M, and 10(-5) M.
Study: 8880837
Drug: Negative control:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Negative control: IM in neutral solution injected into normal skin continuously infiltrated with buffer solution at pH 7.4.
Study: 23429588
Drug: combination treprostinil
Normalized name: Treprostinil
DrugBank: Treprostinil (DB00374)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: combination treprostinil diolamine and sildenafil
Study: 17320023
Drug: Intravenous ibandronate
Normalized name: ibandronate
DrugBank: Ibandronate (DB00710)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous ibandronate
Study: 11713443
Drug: Omeprazole, amoxicillin,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole, amoxicillin, and clarithromycin (OAC) for 7 days
Study: 11713443
Drug: Amoxicillin and
Normalized name: omeprazole, amoxicillin and rifabutin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amoxicillin and clarithromycin (AC) for 7 days
Study: 1401761
Drug: Triptoreline 0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triptoreline 0.1 mg subcutaneously three times in one day at 8 hour intervals
Study: 2416164
Drug: Synthetic platelet
Normalized name: platelet glycoprotein VI
Approvals — FDA: no, EMA: no, PMDA: no
Description: Synthetic platelet activating factor (PAF-acether) intradermal injections of 10-100 ng
Study: 2416164
Drug: Local administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Local administration of H1 antihistamine mepyramin
Study: 15915393
Drug: Propofol (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propofol (0.5 mg/kg IV followed by titration)
Study: 15915393
Drug: Midazolam (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midazolam (1 mg IV every 2 minutes)
Study: 10994627
Drug: Child stage
Normalized name: Senna-Relief Childs
Approvals — FDA: no, EMA: no, PMDA: no
Description: Child stage B/C cirrhosis patients with creatinine > or = 1.4 mg/dl
Study: 1843597
Drug: Toloxatone (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Toloxatone (400 mg daily for 6 weeks)
Study: 3922214
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of Cytoxan, Hexamethylmelamine, and Fluorouracil (CHF)
Study: 3922214
Drug: L-phenylalanine mustard
Normalized name: L-Phenylalanine mustard
DrugBank: Melphalan (DB01042)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: L-phenylalanine mustard (L-pam)
Study: 3922214
Drug: CHF as
Normalized name: CHF 4227
DrugBank: CHF 4227 (DB05882)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CHF as a second-line therapy
Study: 3922214
Drug: L-pam in
Normalized name: L-PAM
DrugBank: Melphalan (DB01042)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: L-pam in patients with complete resection of less than 2 cm residual disease
Study: 29224127
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy with etanercept and methotrexate
Study: 24395436
Drug: 6MP starting
Normalized name: 2-Amino 6MP
DrugBank: Tioguanine (DB00352)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6MP starting dose <75 mg/m(2)/day in ALL2000 cohort
Study: 24395436
Drug: 6MP starting
Normalized name: 2-Amino 6MP
DrugBank: Tioguanine (DB00352)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6MP starting dose 75 mg/m(2)/day in ALL92 cohort
Study: 21269349
Drug: Triple combination
Normalized name: Adrenergics in combination with anticholinergics incl. triple combinations with corticosteroids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple combination (TC) cream and intense pulsed light (IPL)
Study: 21269349
Drug: Inactive control
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inactive control cream and intense pulsed light (IPL)
Study: 9013270
Drug: Enalapril (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enalapril (5 mg) + Prazosin (1 mg)
Study: 1393155
Drug: Tactiling (speechreading
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tactiling (speechreading with tactile supplement)
Study: 18022341
Drug: Regular treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regular treatment from GPs
Study: 16208051
Drug: Carbamazepine (CBZ)
Normalized name: Carbamazepine
DrugBank: Carbamazepine (DB00564)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Carbamazepine (CBZ) therapy at a dose of 13.1 mg/dL
Study: 9925135
Drug: 34 g
Normalized name: Droplet Micron Pen Needles 34 g X 3.5 mm
Approvals — FDA: no, EMA: no, PMDA: no
Description: 34 g conventional soy
Study: 9925135
Drug: 80 g
Normalized name: PEG-80 GLYCERYL COCOATE
Approvals — FDA: no, EMA: no, PMDA: no
Description: 80 g conventional soy
Study: 6794365
Drug: Valproic acid
Normalized name: Valproic Acid
DrugBank: Valproic acid (DB00313)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Valproic acid administered under fasting conditions (250 mg soft-gelatin capsules)
Study: 6794365
Drug: Valproic acid
Normalized name: Valproic Acid
DrugBank: Valproic acid (DB00313)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Valproic acid administered under nonfasting conditions (250 mg soft-gelatin capsules)
Study: 6794365
Drug: Valproic acid
Normalized name: Valproic Acid
DrugBank: Valproic acid (DB00313)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Valproic acid administered under nonfasting conditions (250 mg soft-gelatin capsules, excluding one subject who exercised)
Study: 6794365
Drug: Valproic acid
Normalized name: Valproic Acid
DrugBank: Valproic acid (DB00313)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Valproic acid administered under fasting and nonfasting conditions
Study: 6794365
Drug: Valproic acid
Normalized name: Valproic Acid
DrugBank: Valproic acid (DB00313)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Valproic acid administered with food
Study: 21501216
Drug: Atorvastatin (10,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin (10, 20 or 40 mg day(‐1)) with 300 ml day(‐1) of 100% grapefruit juice for 90 days
Study: 21501216
Drug: Atorvastatin (50%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin (50% reduced dose) with 300 ml day(‐1) of 100% grapefruit juice for 90 days
Study: 14586484
Drug: Antidepressants (specifics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antidepressants (specifics not provided), often in combination with mood stabilizers
Study: 10669337
Drug: Hydroxyurea/didanosine combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydroxyurea/didanosine combination therapy
Study: 9065377
Drug: Bromfenac sodium
Normalized name: Bromfenac Sodium
DrugBank: Bromfenac (DB00963)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Bromfenac sodium 10 mg
Study: 9065377
Drug: Bromfenac sodium
Normalized name: Bromfenac Sodium
DrugBank: Bromfenac (DB00963)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Bromfenac sodium 50 mg
Study: 9065377
Drug: Naproxen sodium
Normalized name: Naproxen Sodium
DrugBank: Naproxen (DB00788)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Naproxen sodium 550 mg loading/275 mg repeat doses
Study: 8380540
Drug: Acyclovir, 400
Normalized name: Acyclovir, 400 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acyclovir, 400 mg twice daily
Study: 3549595
Drug: Cyclospasmol 400
Normalized name: Cyclospasmol 400 MG Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclospasmol 400 mg taken 4 times daily for 12 months
Study: 3549595
Drug: Placebo capsules
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo capsules taken 4 times daily for 12 months
Study: 26949762
Drug: Supportive periodontal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supportive periodontal therapy (SPT) on time for group S1
Study: 24707373
Drug: 0.5 mg
Normalized name: biotin 0.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mg of Estriol as a vaginal cream
Study: 17533394
Drug: Transperineal biopsy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transperineal biopsy in gray zone PSA (4.1 to 10.0 ng/ml)
Study: 15534360
Drug: Hyperfractionated radiotherapy
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hyperfractionated radiotherapy combined with two cycles of concomitant cisplatin (20 mg/m2 on 5 days of weeks 1 and 5)
Study: 15534360
Drug: Hyperfractionated radiotherapy
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hyperfractionated radiotherapy alone (median dose, 74.4 Gy; 1.2 Gy twice daily)
Study: 9467542
Drug: MK-677 25
Normalized name: vitamin MK 7
Approvals — FDA: no, EMA: no, PMDA: no
Description: MK-677 25 mg daily for 8 weeks
Study: 2961787
Drug: DHEA 1600
Approvals — FDA: no, EMA: no, PMDA: no
Description: DHEA 1600 mg/day for 28 days
Study: 28859690
Drug: Staphefekt in
Approvals — FDA: no, EMA: no, PMDA: no
Description: Staphefekt in a cetomacrogol-based cream
Study: 25673113
Drug: Sodium supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sodium supplementation (3 g d(-1), equals 7.6 g d(-1) of salt)
Study: 25673113
Drug: Potassium supplementation
Normalized name: Potassium
DrugBank: Potassium (DB14500)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Potassium supplementation (3 g d(-1))
Study: 23830559
Drug: Mitomycin-C (MMC)
DrugBank: Mitomycin (DB00305)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mitomycin-C (MMC) 0.01% (0.1 mg/mL) for 60 seconds
Study: 23830559
Drug: Mitomycin-C (MMC)
DrugBank: Mitomycin (DB00305)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mitomycin-C (MMC) 0.01% (0.1 mg/mL) for 30 seconds
Study: 23830559
Drug: Mitomycin-C (MMC)
DrugBank: Mitomycin (DB00305)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mitomycin-C (MMC) 0.01% (0.1 mg/mL) for 15 seconds
Study: 21395644
Drug: Neratinib 240
Normalized name: NERATINIB
DrugBank: Neratinib (DB11828)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Neratinib 240 mg alone
Study: 21395644
Drug: Neratinib 240
Normalized name: NERATINIB
DrugBank: Neratinib (DB11828)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Neratinib 240 mg with ketoconazole 400 mg
Study: 18438103
Drug: DTPa and
Approvals — FDA: no, EMA: no, PMDA: no
Description: DTPa and Hib vaccine (mixed prior to administration)
Study: 18438103
Drug: DTPa and
Approvals — FDA: no, EMA: no, PMDA: no
Description: DTPa and Hib vaccine (separate injections)
Study: 16945613
Drug: Calcium (1
Normalized name: hydroxyapatite 275 mg calcium (1,100 mg) ORAL CAPSULE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium (1 g/day as citrate)
Study: 9307820
Drug: In vitro
Normalized name: glucuronidase in vitro test
Approvals — FDA: no, EMA: no, PMDA: no
Description: In vitro measurements with functioning cochlear implant
Study: 30153236
Drug: Tablet computer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet computer (iPad) with low vision applications and instruction in its use, including accessibility features
Study: 24262278
Drug: Sofosbuvir (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sofosbuvir (400 mg once daily) + Ledipasvir (90 mg once daily) + Ribavirin (RBV) for 12 weeks
Study: 24262278
Drug: Sofosbuvir +
Normalized name: Sofosbuvir
DrugBank: Sofosbuvir (DB08934)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Sofosbuvir + GS-9669 (500 mg once daily) + Ribavirin (RBV) for 12 weeks
Study: 20397904
Drug: SRP with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: SRP with Nd:YAG laser treatment
Study: 9839827
Drug: Capsaicin cream
Normalized name: CAPSAICIN 0.1 g in 100 g TOPICAL CREAM [Capsaicin Cream]
DrugBank: Capsaicin (DB06774)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Capsaicin cream (0.025%)
Study: 9839827
Drug: GTN cream
Normalized name: GTN
Approvals — FDA: no, EMA: no, PMDA: no
Description: GTN cream (1.33%)
Study: 9839827
Drug: GTN cream
Normalized name: GTN
Approvals — FDA: no, EMA: no, PMDA: no
Description: GTN cream (1.33%) + Capsaicin cream (0.025%)
Study: 7527418
Drug: Glucose polymer
Normalized name: glucose polymers
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glucose polymer solution (trial G)
Study: 27306256
Drug: Individualized physical
Normalized name: hypochlorite
DrugBank: Hypochlorite (DB11123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Individualized physical therapy (10 sessions)
Study: 25328957
Drug: Integrated cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Integrated cognitive behaviour therapy (CBT) for PTSD and AUD (IT)
Study: 21556834
Drug: Insulin-stimulated glucose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Insulin-stimulated glucose uptake in adipose tissue
Study: 21556834
Drug: Insulin-mediated suppression
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Insulin-mediated suppression of lipolysis and adiponectin metabolism
Study: 21556834
Drug: Hepatic glucose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hepatic glucose metabolism
Study: 15572462
Drug: IVF treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: IVF treatment phases (4 distinct stages)
Study: 10490250
Drug: CharcoAid G
Normalized name: Activated Charcoal 15 GM Oral Granule [CHARCOAID G]
Approvals — FDA: no, EMA: no, PMDA: no
Description: CharcoAid G (CA)
Study: 2017645
Drug: Ceftriaxone (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ceftriaxone (2 g once daily) for 4 weeks
Study: 2017645
Drug: Ceftriaxone (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ceftriaxone (2 g once daily for 2 weeks) followed by oral amoxicillin (1 g four times a day for 2 weeks)
Study: 2017645
Drug: Ceftriaxone (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ceftriaxone (2 g once daily) for 4 weeks and Ceftriaxone followed by amoxicillin
Study: 6124760
Drug: Bovine insulin
Normalized name: Bovine insulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bovine insulin
Study: 25041859
Drug: Weekly adalimumab
Normalized name: Adalimumab
DrugBank: Adalimumab (DB00051)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Weekly adalimumab dosing
Study: 25041859
Drug: Every other
Normalized name: Ether
DrugBank: Diethyl ether (DB13598)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Every other week (EOW) adalimumab dosing
Study: 12536508
Drug: Insulin and
Normalized name: Isophane insulin and porcine regular insulin only product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Insulin and hyperosmotic glucose solution
Study: 12536508
Drug: Moist burn
Normalized name: Burn Jel Plus
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Moist burn ointment (Control)
Study: 27905102
Drug: Pre-treatment elevated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pre-treatment elevated HbF
Study: 26451070
Drug: High-dose vitamin
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose vitamin D (4000 IU/d)
Study: 26451070
Drug: Low-dose vitamin
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose vitamin D (400 IU/d)
Study: 21056842
Drug: Chinese herbs
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chinese herbs extra group (CH) with complementary therapies of Chinese medicine and standard treatment
Study: 21056842
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment only group (ST)
Study: 17384341
Drug: Individual initiation
Normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Individual initiation of bedtime insulin glargine
Study: 17384341
Drug: Group initiation
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group initiation of bedtime insulin glargine
Study: 7572013
Drug: 0.4 mg
Normalized name: biotin 0.4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.4 mg buprenorphine (group B)
Study: 6894099
Drug: tolamolol 200
Approvals — FDA: no, EMA: no, PMDA: no
Description: tolamolol 200 mg
Study: 31806605
Drug: Corticosteroid/alkylating-agent therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Corticosteroid/alkylating-agent therapy
Study: 15311105
Drug: Troglitazone (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Troglitazone (400 mg) and antihypertensive drugs
Study: 15311105
Drug: Antihypertensive drugs
Normalized name: ANTIHYPERTENSIVES
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antihypertensive drugs only (Control group)
Study: 8988115
Drug: Topical 0.2%
Normalized name: coal tar topical 0.2% topical soap
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical 0.2% GTN ointment
Study: 30451888
Drug: Mavoglurant (up
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mavoglurant (up to 100 mg bid for up to 34 months)
Study: 24920884
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose (fluticasone 1,000 μg + salmeterol 100 μg/day)
Study: 24920884
Drug: Medium dose
Normalized name: TRIGLYCERIDES,MEDIUM CHAIN
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medium dose (fluticasone 500 μg + salmeterol 100 μg/day)
Study: 18700898
Drug: Parnaparin-MMX (70,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Parnaparin-MMX (70, 140, and 210 mg once daily) for 8 weeks
Study: 8122604
Drug: dl-sotalol 80
Normalized name: sotalol hydrochloride 80 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: dl-sotalol 80 mg/day
Study: 8122604
Drug: dl-sotalol 160
Normalized name: sotalol hydrochloride 160 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: dl-sotalol 160 mg/day
Study: 8122604
Drug: digoxin monotherapy
Normalized name: Digoxin
DrugBank: Digoxin (DB00390)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: digoxin monotherapy (placebo)
Study: 2486654
Drug: Morphine hydrochloride
Normalized name: Morphine hydrochloride
DrugBank: Morphine (DB00295)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Morphine hydrochloride (50 micrograms/kg)
Study: 700598
Drug: Trospium chloride
Normalized name: Trospium Chloride
DrugBank: Trospium (DB00209)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Trospium chloride (oral application)
Study: 700598
Drug: Trospium chloride
Normalized name: Trospium Chloride
DrugBank: Trospium (DB00209)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Trospium chloride (parenteral application)
Study: 31699751
Drug: Study-approved lotion
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Study-approved lotion
Study: 31699751
Drug: Study-approved cream
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Study-approved cream
Study: 31699751
Drug: Study-approved gel
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Study-approved gel
Study: 31699751
Drug: Study-approved ointment
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Study-approved ointment
Study: 31699751
Drug: Standard care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard care (topical corticosteroids)
Study: 31699751
Drug: Treatment use
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment use
Study: 28076735
Drug: Medication management
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medication management plans completed by a pharmacist (intervention)
Study: 25817213
Drug: Endodontic treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endodontic treatment and scaling and root planning (SRP) performed simultaneously
Study: 25817213
Drug: SRP performed
Normalized name: Perform
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: SRP performed 3 months after endodontic treatment